Table 1. Clinical use of IVIG: US FDA-approved and off-label treatments [6,14-16]

US FDA-approved
Primary immunodeficiency disorders such as CVID, XLA, and WAS Kawasaki disease Immune thrombocytopenic purpura B-cell chronic lymphocytic leukemia Chronic inflammatory demyelinating polyneuropathy (CIDP) Multifocal motor neuropathy (MMN) Bone marrow transplantation HIV infection

Neurology
Guillain Barre syndrome, myasthenia gravis, Lennox gastaut seizure, Landau kleffner seizure, opsoclonus myoclonus ataxia, PANDAS

Hematology
Pure red cell aplasia, pure white cell aplasia, immune neutropenia, hemolytic anemia

Neonatology
Hemolytic disease of newborn due to Rh and ABO incompatibility, neonatal alloimmune thrombocytopenic purpura, bacterial sepsis in preterm

Others
Myocarditis, systemic lupus erythematosus, dermatomyositis, autoimmune uveitis, streptococcal toxic shock syndrome, toxic epidermal necrolysis, immune urticaria, atopic dermatitis, pyoderma gangrenosum

IVIG: intravenous immunoglobulin; FDA: Food and Drug Administration; CVID: common variable immunodeficiency; XLA: X-Linked agammaglobulinemia; WAS: Wiskott-Aldrich syndrome; HIV: human immunodeficiency virus; PANDAS: Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection.